Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.

摘要: In the adjuvant setting, third-generation aromatase inhibitors (AIs) anastrozole, letrozole and exemestane are recommended at some point during treatment, either in upfront, switch after tamoxifen or extended treatment setting postmenopausal patients with hormone receptor-positive early breast cancer. AIs have demonstrated superior disease-free survival overall benefit-to-risk profiles compared tamoxifen. Potential adverse events, including cardiovascular (CV) side effects, should be considered long-term management of undergoing AIs. reduce estrogen levels by inhibiting enzyme, thus reducing circulating estrogen. This further reduction may potentially increase risk developing CV disease. systematic review evaluated published clinical data for changes plasma lipoproteins ischaemic events therapy The electronic databases MEDLINE, EMBASE, Derwent Drug File BIOSIS were searched to identify English-language articles from January 1998 15 April 2011 that reported on and/or events. Overall, available did not show any definitive patterns suggest an unfavourable effect baseline follow-up assessment Changes occurred observed soon initiation AI generally remained stable throughout studies. Available do support a substantial associated therapy; however, studies longer required better characterize profile